Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Authors: Benqiang Rao, Minyan Han, Lei Wang, Xiaoyan Gao, Jun Huang, Meijin Huang, Huanliang Liu, Jianping Wang

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

To evaluate the objective clinical outcomes of active specific immunotherapy (ASI) in advanced colorectal cancer (advanced CRC) and suspected minimal residual colorectal cancer (suspected minimal residual CRC).

Methods

A search was conducted on Medline and Pub Med from January 1998 to January 2010 for original studies on ASI in colorectal cancer (CRC). All articles included in this study were assessed with the application of predetermined selection criteria and were divided into two groups: ASI in advanced CRC and ASI in suspected minimal residual CRC. For ASI in suspected minimal residual CRC, a meta-analysis was executed with results regarding the overall survival (OS) and disease-free survival (DFS). Regarding ASI in advanced colorectal cancer, a system review was performed with clinical outcomes.

Results

1375 colorectal carcinoma patients with minimal residual disease have been enrolled in Meta-analysis. A significantly improved OS and DFS was noted for suspected minimal residual CRC patients utilizing ASI (For OS: HR = 0.76, P = 0.007; For DFS: HR = 0.76, P = 0.03). For ASI in stage II suspected minimal residual CRC, OS approached significance when compared with control (HR = 0.71, P = 0.09); however, the difference in DFS of ASI for the stage II suspected minimal residual CRC reached statistical significance (HR = 0.66, P = 0.02). For ASI in stage III suspected minimal residual CRC compared with control, The difference in both OS and DFS achieved statistical significance (For OS: HR = 0.76, P = 0.02; For DFS: HR = 0.81, P = 0.03). 656 advanced colorectal patients have been evaluated on ASI in advanced CRC. Eleven for CRs and PRs was reported, corresponding to an overall response rate of 1.68%. No serious adverse events have been observed in 2031 patients.

Conclusions

It is unlikely that ASI will provide a standard complementary therapeutic approach for advanced CRC in the near future. However, the clinical responses to ASI in patients with suspected minimal residual CRC have been encouraging, and it has become clear that immunotherapy works best in situations of patients with suspected minimal residual CRC.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
Kerr D: Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer. 2003, 3: 615-622. 10.1038/nrc1147.CrossRefPubMed
3.
Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A, Muller HH: Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol. 2000, 27: 112-119.PubMed
4.
Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW: Colorectal cancer. Lancet. 2005, 365: 153-165. 10.1016/S0140-6736(05)17706-X.CrossRefPubMed
5.
Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D: Systemic treatment of colorectal cancer. Eur J Cancer. 2002, 38: 1000-1015. 10.1016/S0959-8049(02)00062-X.CrossRefPubMed
6.
7.
Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst. 2004, 96: 1128-1132. 10.1093/jnci/djh220.CrossRefPubMed
8.
Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004, 90: 1003-1010. 10.1038/sj.bjc.6601619.PubMedCentralCrossRefPubMed
9.
Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B: Adjuvant 5-uorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998, 90: 1810-1816. 10.1093/jnci/90.23.1810.CrossRefPubMed
10.
Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK: Current Immunotherapeutic Strategies in Colon Cancer. Surg Oncol Clin N Am. 2007, 16: 873-900. 10.1016/j.soc.2007.07.005.CrossRefPubMed
11.
Mocellin S, Mandruzzato S, Bronte V, Marincola FM: Cancer vaccines: pessimism in check. Nat Med. 2004, 10: 1278-1279. 10.1038/nm1204-1278.CrossRefPubMed
12.
13.
Nagorsen D, Thiel E: Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer. Clin Cancer Res. 2006, 12: 3064-3069. 10.1158/1078-0432.CCR-05-2788.CrossRefPubMed
14.
Alejandro R, Jadad MD, DPhil R, Andrew Moore DPhil, Dawn Carroll RGN, Crispin Jenkinson DPhil D, John M, Reynolds DPhil, David J, Gavaghan DPhil, Henry J, McQuay DM: Assessing the quality of reports of randomized clinical t rials: Is blinding necessary ?. Control Clinic Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.CrossRef
15.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21: 1539-1558. 10.1002/sim.1186.CrossRefPubMed
16.
Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG: Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000, 18: 148-153.PubMed
17.
Uyl-de Groot CA, Vermorken JB, Hanna MG, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM: Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benets. Vaccine. 2005, 23: 2379-2387. 10.1016/j.vaccine.2005.01.015.CrossRefPubMed
18.
Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009, 58: 61-69. 10.1007/s00262-008-0526-1.CrossRefPubMed
19.
Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal Antibody Therapy for Resected Dukes' Colorectal Cancer:Seven-Year Outcome of a Multicenter Randomized Trial. J Clin Oncol. 1998, 16: 1788-1794.PubMed
20.
Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet. World J Gastroenterol. 2003, 9: 495-498.PubMedCentralCrossRefPubMed
21.
Tarasov VA, Filatov MV, Kisliakova TV, Noskov FS, Koloskov AV, Stavrovietski VV, Onikienko SB, Kletchikov VZ, Lvov IV, Yu Varfolomeeva E, Blizniukov OP, Levina VV, Kiselevski MV: Combined Surgical and Immunotherapeutic Treatment of Patients with Fourth Stage Colon Cancer. Hybridoma. 1999, 18: 99-102. 10.1089/hyb.1999.18.99.CrossRefPubMed
22.
Bhattachary-Chatterjee M, Nath Baral R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, Foon KA: Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple- epitope antigen vaccine. Cancer Immunol Immunother. 2000, 49: 133-141. 10.1007/s002620050612.CrossRefPubMed
23.
Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF: Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients. Clin Cancer Res. 2002, 8: 2782-2787.PubMed
24.
Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 2001, 98: 8809-8814. 10.1073/pnas.141226398.PubMedCentralCrossRefPubMed
25.
Hörig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. 2000, 49: 504-514.CrossRefPubMed
26.
Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother. 2002, 51: 99-106. 10.1007/s00262-001-0257-z.CrossRefPubMed
27.
Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003, 9: 495-498.PubMedCentralCrossRefPubMed
28.
Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, Whang-Peng J: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004, 10: 2645-2651. 10.1158/1078-0432.CCR-03-0430.CrossRefPubMed
29.
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Onco. 2000, 18: 3964-3973.
30.
Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005, 23: 720-731. 10.1200/JCO.2005.10.206.CrossRefPubMed
31.
Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H: Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2004, 53: 609-616. 10.1007/s00262-003-0491-7.CrossRefPubMed
32.
Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001, 7: 3950-3962.PubMed
33.
Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK: Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 2003, 21: 341-349. 10.1081/CNV-120018224.CrossRefPubMed
34.
Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK: Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005, 11: 3017-3024. 10.1158/1078-0432.CCR-04-2172.CrossRefPubMed
35.
Rains N, Cannan RJ, Chen W, Stubbs RS: Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology. 2001, 48: 347-351.PubMed
36.
Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001, 7: 2277-2284.PubMed
37.
Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Harada M, Itoh K, Todo S: A phase I trial of cytotoxic T- lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer. 2004, 90: 1334-1342. 10.1038/sj.bjc.6601711.PubMedCentralCrossRefPubMed
38.
Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004, 2: 19-24. 10.1186/1479-5876-2-19.PubMedCentralCrossRefPubMed
39.
Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol. 2004, 24: 909-917.PubMed
40.
von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res. 2000, 6: 2219-2228.PubMed
41.
Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Larrañga J: Advanced Colon Cancer: Antiprogressive Immunotherapy Using an Autologous Hemoderivative. Med Oncol. 2006, 23: 91-104. 10.1385/MO:23:1:91.CrossRefPubMed
42.
Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, Rosenberg J: Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. oncol Rep. 2008, 20: 1305-1311.PubMed
43.
Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW: Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial. Clin Cancer Res. 2006, 12: 3416-3424. 10.1158/1078-0432.CCR-05-2732.CrossRefPubMed
44.
Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, van der Melief CJ: Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer. Clin Cancer Res. 2009, 15: 1086-1091. 10.1158/1078-0432.CCR-08-2227.CrossRefPubMed
45.
Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G: Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother. 2007, 56: 2003-2016. 10.1007/s00262-007-0299-y.CrossRefPubMed
46.
Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, Li G: Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer. Mol Ther. 2008, 164: 782-790. 10.1038/mt.2008.1.CrossRef
47.
Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L: Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides. J Immunother. 2007, 30: 762-772. 10.1097/CJI.0b013e318133451c.CrossRefPubMed
48.
Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, Tanaka J, Yoshikawa N, Nishikawa T, Shuno Y, Todo T, Saito N, Takahashi K: Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer. 2008, 44: 383-390. 10.1016/j.ejca.2007.10.018.CrossRefPubMed
49.
Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV: Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother. 2007, 61: 125-130. 10.1016/j.biopha.2006.09.016.CrossRefPubMed
50.
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9: 533-542. 10.1016/S1470-2045(08)70107-4.CrossRefPubMed
51.
Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Neubauer A, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG: Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial. Hum Gene Ther. 2001, 12: 267-278. 10.1089/10430340150218404.CrossRefPubMed
52.
Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ: Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther. 2003, 10: 509-517. 10.1038/sj.cgt.7700600.CrossRefPubMed
53.
Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF: Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2003, 21: 1498-1504. 10.1200/JCO.2003.09.114.CrossRefPubMed
54.
Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'hermenier C, Bellenger K, Campbell M, Powles T, Highley M, Bower M, Mouritsen S, Feldmann M, Coombes RC: Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother. 2005, 54: 848-857. 10.1007/s00262-005-0661-x.CrossRefPubMed
55.
Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK: Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules. Clin Cancer Res. 2005, 11: 3017-3024. 10.1158/1078-0432.CCR-04-2172.CrossRefPubMed
56.
Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M: Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006, 55: 268-276. 10.1007/s00262-005-0021-x.CrossRefPubMed
57.
Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, Whang-Peng J: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A 2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004, 10: 2645-2651. 10.1158/1078-0432.CCR-03-0430.CrossRefPubMed
58.
Zbar AP, Thomas H, Wilkinson RW, Wadhwa M, Syrigos KN, Ross EL, Dilger P, Allen-Mersh TG, Kmiot WA, Epenetos AA, Snary D, Bodmer WF: Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study. Int J Colorectal Dis. 2005, 20: 403-414. 10.1007/s00384-004-0726-x.CrossRefPubMed
59.
Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM: Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004, 22: 773-780. 10.1016/j.vaccine.2003.08.021.CrossRefPubMed
60.
Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF: Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res. 1999, 5: 2330-2337.PubMed
61.
Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999, 5: 1331-1338.PubMed
62.
Samonigg H, Wilders-Truschnig M, Kuss I, Plot R, Stöger H, Schmid M, Bauernhofer T, Tiran A, Pieber T, Havelec L, Loibner H: A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother. 1999, 22: 481-488. 10.1097/00002371-199911000-00002.PubMed
63.
Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, Brostoff S, Carlo DJ, Royston I, Gold DP: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res. 1999, 5: 2359-2365.PubMed
64.
Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS: Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immuno ther. 1999, 22: 251-259. 10.1097/00002371-199905000-00008.CrossRef
65.
Hanna MG, Hoover HC, Pinedo HM, Finer M: Active Specific Immunotherapy with Autologous Tumor Cell Vaccines for Stage II Colon Cancer: Logistics, Efficacy, Safety and Immunological Pharmacodynamics. Hum Vaccin. 2006, 2: 185-191.CrossRefPubMed
66.
Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998, 339: 223-228. 10.1056/NEJM199807233390403.CrossRefPubMed
67.
O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445: 106-110.CrossRefPubMed
68.
von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001, 7: 1181-1191.PubMed
69.
Beck K, Blansfield J, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006, 24: 2283-2289. 10.1200/JCO.2005.04.5716.PubMedCentralCrossRefPubMed
70.
Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed
71.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2006, 56: 641-648. 10.1007/s00262-006-0225-8.CrossRefPubMed
72.
Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005, 28: 582-592. 10.1097/01.cji.0000175468.19742.10.PubMedCentralCrossRefPubMed
73.
O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007, 13: 958-964.CrossRefPubMed
74.
Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005, 115: 3623-3633. 10.1172/JCI25947.PubMedCentralCrossRefPubMed
75.
Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res. 2005, 11: 1474-8142. 10.1158/1078-0432.CCR-03-0817.CrossRefPubMed
76.
Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol. 1997, 15: 617-648. 10.1146/annurev.immunol.15.1.617.CrossRefPubMed
Metadata
Title
Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
Authors
Benqiang Rao
Minyan Han
Lei Wang
Xiaoyan Gao
Jun Huang
Meijin Huang
Huanliang Liu
Jianping Wang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-17

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO)

Research

Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit

Research

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study

Research

Combination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke

Research

Adipose-Derived Mesenchymal Stem Cell Protects Kidneys against Ischemia-Reperfusion Injury through Suppressing Oxidative Stress and Inflammatory Reaction

Methodology

Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits